These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32031967)

  • 21. Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease.
    Afshinnia F; Zeng L; Byun J; Gadegbeku CA; Magnone MC; Whatling C; Valastro B; Kretzler M; Pennathur S;
    Am J Nephrol; 2017; 46(1):73-81. PubMed ID: 28668952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma myeloperoxidase is related to the severity of coronary artery disease.
    Düzgünçinar O; Yavuz B; Hazirolan T; Deniz A; Tokgözoğlu SL; Akata D; Demirpençe E
    Acta Cardiol; 2008 Apr; 63(2):147-52. PubMed ID: 18468192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease.
    Haraguchi Y; Toh R; Hasokawa M; Nakajima H; Honjo T; Otsui K; Mori K; Miyamoto-Sasaki M; Shinohara M; Nishimura K; Ishida T; Hirata K
    Atherosclerosis; 2014 Jun; 234(2):288-94. PubMed ID: 24704632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients.
    Roman RM; Camargo PV; Borges FK; Rossini AP; Polanczyk CA
    Coron Artery Dis; 2010 May; 21(3):129-36. PubMed ID: 20305551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors influencing local and systemic levels of plasma myeloperoxidase in ST-segment elevation acute myocardial infarction.
    Marshall CJ; Nallaratnam M; Mocatta T; Smyth D; Richards M; Elliott JM; Blake J; Winterbourn CC; Kettle AJ; McClean DR
    Am J Cardiol; 2010 Aug; 106(3):316-22. PubMed ID: 20643239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trans-vessel gradient of myeloperoxidase in coronary artery disease.
    Alipour A; Ribalta J; Njo TL; Janssen HW; Birnie E; van Miltenburg AJ; Elte JW; Castro Cabezas M
    Eur J Clin Invest; 2013 Sep; 43(9):920-5. PubMed ID: 23869443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of myeloperoxidase concentration in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Kacprzak M; Zielinska M
    Int J Cardiol; 2016 Nov; 223():452-457. PubMed ID: 27544604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determining myeloperoxidase activity and protein concentration in a single assay: Utility in biomarker and therapeutic studies.
    Russell M; Prokoph N; Henderson N; Eketjäll S; Balendran CA; Michaëlsson E; Fidock M; Hughes G
    J Immunol Methods; 2017 Oct; 449():76-79. PubMed ID: 28713008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated levels of myeloperoxidase, white blood cell count and 3-chlorotyrosine in Taiwanese patients with acute myocardial infarction.
    Cheng ML; Chen CM; Gu PW; Ho HY; Chiu DT
    Clin Biochem; 2008 May; 41(7-8):554-60. PubMed ID: 18314009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between myeloperoxidase polymorphisms and its plasma levels with severity of coronary artery disease.
    Wainstein RV; Wainstein MV; Ribeiro JP; Dornelles LV; Tozzati P; Ashton-Prolla P; Ewald IP; Vietta G; Polanczyk CA
    Clin Biochem; 2010 Jan; 43(1-2):57-62. PubMed ID: 19651119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of association between plasma myeloperoxidase levels and angiographic severity of coronary artery disease in patients with acute coronary syndrome.
    de Azevedo Lucio E; Gonçalves SC; Ribeiro JP; Nunes GL; de Oliveira JR; Araujo GN; Wainstein MV
    Inflamm Res; 2011 Feb; 60(2):137-42. PubMed ID: 20848159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Total, Active, and Specific Myeloperoxidase Levels in Women with and without Endometriosis.
    O DF; Waelkens E; Peterse DP; Lebovic D; Meuleman C; Tomassetti C; Peeraer K; Alvarez Real A; Bosseloir A; D'Hooghe T; Fassbender A
    Gynecol Obstet Invest; 2018; 83(2):133-139. PubMed ID: 28511185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of myeloperoxidase -463 G/A gene polymorphism and plasma levels on coronary artery disease.
    Ergen A; İsbir S; Timirci Ö; Tekeli A; İsbir T
    Mol Biol Rep; 2011 Feb; 38(2):887-91. PubMed ID: 20568015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liberation of vessel-adherent myeloperoxidase reflects plaque burden in patients with stable coronary artery disease.
    Rudolph TK; Schaper N; Klinke A; Demir C; Goldmann B; Lau D; Köster R; Hellmich M; Meinertz T; Baldus S; Rudolph V
    Atherosclerosis; 2013 Dec; 231(2):354-8. PubMed ID: 24267251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myeloperoxidase and coronary arterial disease: from research to clinical practice.
    Roman RM; Wendland AE; Polanczyk CA
    Arq Bras Cardiol; 2008 Jul; 91(1):e11-9. PubMed ID: 18660935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Correlation between MPO 129 A/G polymorphism and severity of coronary artery disease].
    Hu JL; Xu JB; Zhou X; Jiang TM; Li YM; Zhang M
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2011 Aug; 27(3):306-10. PubMed ID: 22097722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of myeloperoxidase as a risk marker for atherosclerosis.
    Nambi V
    Curr Atheroscler Rep; 2005 Mar; 7(2):127-31. PubMed ID: 15727728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salivary Matrix Metalloproteinase-8 and -9 and Myeloperoxidase in Relation to Coronary Heart and Periodontal Diseases: A Subgroup Report from the PAROKRANK Study (Periodontitis and Its Relation to Coronary Artery Disease).
    Rathnayake N; Gustafsson A; Norhammar A; Kjellström B; Klinge B; Rydén L; Tervahartiala T; Sorsa T;
    PLoS One; 2015; 10(7):e0126370. PubMed ID: 26132583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salivary and plasma levels of matrix metalloproteinase-9 and myeloperoxidase at rest and after acute physical exercise in patients with coronary artery disease.
    Mahmood Z; Enocsson H; Bäck M; Chung RWS; Lundberg AK; Jonasson L
    PLoS One; 2019; 14(2):e0207166. PubMed ID: 30726210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An immunological method to combine the measurement of active and total myeloperoxidase on the same biological fluid, and its application in finding inhibitors which interact directly with the enzyme.
    Franck T; Minguet G; Delporte C; Derochette S; Zouaoui Boudjeltia K; Van Antwerpen P; Gach O; Deby-Dupont G; Mouithys-Mickalad A; Serteyn D
    Free Radic Res; 2015 Jun; 49(6):790-9. PubMed ID: 25968947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.